| Primary |
| Product Used For Unknown Indication |
60.7% |
| Plasma Cell Myeloma |
33.9% |
| Pain |
1.2% |
| Nausea |
0.7% |
| Hypertension |
0.6% |
| Prophylaxis |
0.5% |
| Anxiety |
0.4% |
| Constipation |
0.2% |
| Insomnia |
0.2% |
| Amyloidosis |
0.2% |
| Antiviral Prophylaxis |
0.2% |
| Chronic Obstructive Pulmonary Disease |
0.2% |
| Deep Vein Thrombosis |
0.2% |
| Haemorrhoids |
0.2% |
| Infection Prophylaxis |
0.2% |
| Neutropenia |
0.2% |
| Vomiting |
0.2% |
| Analgesic Therapy |
0.1% |
| Atrial Fibrillation |
0.1% |
| Dyspnoea |
0.1% |
|
| Death |
24.1% |
| Plasma Cell Myeloma |
23.0% |
| Pneumonia |
8.9% |
| White Blood Cell Count Decreased |
5.8% |
| Rash |
5.5% |
| Pruritus |
3.4% |
| Full Blood Count Decreased |
3.1% |
| Pancytopenia |
3.1% |
| Pyrexia |
2.4% |
| Renal Failure |
2.4% |
| Unevaluable Event |
2.4% |
| Platelet Count Decreased |
2.2% |
| Thrombocytopenia |
2.2% |
| Drug Intolerance |
1.9% |
| Thrombosis |
1.9% |
| Neuropathy Peripheral |
1.7% |
| Renal Disorder |
1.7% |
| Sepsis |
1.7% |
| Fatigue |
1.4% |
| Oedema Peripheral |
1.4% |
|
| Secondary |
| Product Used For Unknown Indication |
69.0% |
| Plasma Cell Myeloma |
20.3% |
| Pain |
2.0% |
| Nausea |
1.2% |
| Prophylaxis |
1.1% |
| Anxiety |
0.7% |
| Hypertension |
0.6% |
| White Blood Cell Count Decreased |
0.6% |
| Deep Vein Thrombosis |
0.5% |
| Blood Pressure |
0.4% |
| Diarrhoea |
0.4% |
| Haematocrit Decreased |
0.4% |
| Haemoglobin Decreased |
0.4% |
| Haemorrhoids |
0.4% |
| Neutrophil Count Decreased |
0.4% |
| Platelet Count Decreased |
0.4% |
| Constipation |
0.3% |
| Insomnia |
0.3% |
| Neuropathy Peripheral |
0.3% |
| Supplementation Therapy |
0.3% |
|
| Plasma Cell Myeloma |
25.0% |
| Pancytopenia |
17.2% |
| Death |
14.8% |
| White Blood Cell Count Decreased |
5.5% |
| Sepsis |
4.7% |
| Pneumonia |
3.9% |
| Bone Marrow Failure |
3.1% |
| Femur Fracture |
3.1% |
| Drug Ineffective |
2.3% |
| Hyperventilation |
2.3% |
| Pyrexia |
2.3% |
| Septic Shock |
2.3% |
| Thrombosis |
2.3% |
| Clostridium Difficile Colitis |
1.6% |
| Full Blood Count Decreased |
1.6% |
| Gait Disturbance |
1.6% |
| Invasive Ductal Breast Carcinoma |
1.6% |
| Myalgia |
1.6% |
| Myocardial Infarction |
1.6% |
| Neuropathy Peripheral |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
79.4% |
| Amyloidosis |
8.8% |
| Plasma Cell Myeloma |
8.8% |
| Hiv Infection |
2.9% |
|
| Plasma Cell Myeloma |
50.0% |
| Thrombophlebitis Superficial |
25.0% |
| Thrombosis |
25.0% |
|
| Interacting |
| Plasma Cell Myeloma |
50.0% |
| Product Used For Unknown Indication |
50.0% |
|
|
